KRASG12C inhibitor: combing for combination.

Abstract excerpt

Oncogenic mutation in KRAS is one of the most common alterations in human cancer. After decades of extensive research and unsuccessful drug discovery programs, therapeutic targeting of KRAS mutant tumour is at an exciting juncture. The discovery of mutation-specific inhibitors of KRASG12C and early positive findings from clinical trials has raised the hope of finally having a drug to treat a significant segment...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autophagy
• Share to Cell Lineage
• Share to Clinical Trials as Topic